Effect of ACE Inhibitors on GFR in Renal Artery Stenosis

Mechanism of Action

In renal artery stenosis, maintenance of GFR becomes highly dependent on angiotensin II (Ang II), which constricts the efferent arteriole to a greater extent than the afferent arteriole, thereby maintaining glomerular hydrostatic pressure despite reduced renal perfusion 1
ACE inhibitors block the formation of Ang II, leading to vasodilation of the efferent arteriole, which reduces intraglomerular pressure and subsequently decreases GFR 2
This effect is particularly pronounced in high-grade bilateral renal artery stenosis or stenosis of a dominant or single kidney 1

When ACE inhibitors are administered in renal artery stenosis, they cause predominant efferent arteriolar vasodilation 2
Reduction in glomerular capillary pressure occurs due to ACE inhibitors 2
Potential development of acute renal failure (ARF) can occur when ACE inhibitors are administered in renal artery stenosis 1
The decrease in GFR occurs because renal perfusion pressure cannot be sustained due to the stenosis 3
The compensatory effect of Ang II on the efferent arteriole is blocked by ACE inhibitors 1

ACE inhibitor-induced reduction in GFR can be detected through elevated serum creatinine levels 2
Risk factors for significant GFR reduction include bilateral renal artery stenosis or stenosis of a dominant/single kidney 1
Volume depletion, such as from diuretic therapy, is a risk factor for significant GFR reduction 4
Pre-existing hypotension is a risk factor for significant GFR reduction 1
Concomitant use of NSAIDs or other vasoconstrictor agents is a risk factor for significant GFR reduction 5

A 10-20% increase in serum creatinine is commonly observed and expected after initiating ACE inhibitor therapy in patients with renal insufficiency 2
In renal artery stenosis, the decrease in GFR may be more pronounced and potentially lead to acute renal failure 1
Monitoring serum creatinine and electrolyte levels before and one week after starting ACE inhibitor therapy is recommended 2
ACE inhibitor-induced renal dysfunction typically reverses with discontinuation of the medication or volume replenishment 2

In patients with heart failure without renal artery stenosis, ACE inhibitors may improve or maintain GFR 2
In patients with chronic kidney disease without renal artery stenosis, the initial decrease in GFR is usually transient and followed by stabilization or improvement due to renoprotective effects 2

Angiotensin II constricts the efferent arteriole to a greater extent than the afferent arteriole, which helps maintain glomerular hydrostatic pressure and GFR despite reduced renal perfusion 6
During states of volume depletion or "dehydration," Angiotensin II helps maintain GFR by preserving glomerular pressure 6

In partial urinary tract obstruction, Angiotensin II activation may have beneficial effects on kidney function 7

A 10-20% increase in serum creatinine is commonly observed after initiating ACE inhibitor therapy, indicating the loss of Angiotensin II's GFR-preserving effect 6
Understanding Angiotensin II's protective role in maintaining GFR explains why ACE inhibitors and ARBs can cause acute kidney injury in certain clinical scenarios 6
Monitoring serum creatinine after initiating ACE inhibitors or ARBs is essential to detect excessive GFR reduction 6
In chronic kidney disease without renal artery stenosis, the initial decrease in GFR with ACE inhibitors is usually transient and followed by stabilization or improvement due to long-term renoprotective effects 6

Screening for bilateral renal artery stenosis or stenosis in a solitary kidney is crucial, as ACE inhibitors are contraindicated in these conditions because GFR becomes entirely angiotensin II-dependent, according to the Kidney International guidelines 8, 9

Hemodialysis is not indicated for a creatinine of 200 μmol/L (2.3 mg/dL) unless there are urgent indications such as severe hyperkalemia unresponsive to medical management, severe metabolic acidosis, uremic symptoms, or volume overload refractory to diuretics, as stated in the Kidney International guidelines 9
Low-dose "renal dose" dopamine has no role in the management of ACE inhibitor-induced renal dysfunction, as it does not improve renal outcomes and may cause harm through arrhythmias and other adverse effects, according to the Kidney International guidelines 8, 9

If bilateral renal artery stenosis is confirmed, ramipril is contraindicated and should not be restarted, as recommended by the Kidney International guidelines 8
The KDIGO guidelines state that ACE inhibitors should not be stopped with modest and stable increases in serum creatinine (up to 30%), but stopped if kidney function continues to worsen, as referenced in the Kidney International guidelines 8, 9

Patients should be counseled to hold ramipril during sick days when at risk for volume depletion (diarrhea, vomiting, reduced oral intake), as recommended by the Kidney International guidelines 8, 9